Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose (Q33738711)

29 July 2017

title

Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose (English)

1 reference

postmenopausal osteoporosis

29 July 2017

0 references

1 reference

8

Caren M Gundberg

1 reference

29 July 2017

7

Bruce W Hollis

1 reference

29 July 2017

Mara J Horwitz

1

1 reference

29 July 2017

Mary Beth Tedesco

2

1 reference

29 July 2017

Adolfo Garcia-Ocaña

3

1 reference

29 July 2017

Susan M Sereika

4

1 reference

29 July 2017

Linda Prebehala

5

1 reference

29 July 2017

Alessandro Bisello

6

1 reference

29 July 2017

Andrew F Stewart

9

1 reference

29 July 2017

language of work or name

English

0 references

publication date

8 January 2010

1 reference

The Journal of Clinical Endocrinology and Metabolism

29 July 2017

published in

1 reference

29 July 2017

volume

95

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

1279-1287

1 reference

Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

The physiology of parathyroid hormone-related protein

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Defining the roles of parathyroid hormone-related protein in normal physiology

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

A cross-sectional study of bone turnover markers in healthy premenopausal women.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Daily and cyclic parathyroid hormone in women receiving alendronate

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunte

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841539

Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis

10 December 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Exogenous PTH and endogenous 1,25-dihydroxyvitamin D are complementary in inducing an anabolic effect on bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid

1 reference

https://pubmed.ncbi.nlm.nih.gov/20061412

12 December 2020

Identifiers

DOI

10.1210/JC.2009-0233

1 reference

29 July 2017

1 reference

29 July 2017

1 reference